Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 1842: Familial demonstration of the involvement of E-cadherine germ-line mutation in inherited invasive lobular breast carcinomas

View through CrossRef
Abstract Introduction Germline mutations of the CDH1 (epithelial cadherin, OMIM 192090) gene have been extensively studied in hereditary diffuse gastric cancer (HDGC) families. Carriers of CDH1 germline mutations have a cumulative gastric cancer risk of 40-67% for men and 63-83% for women. Putative associated risk of lobular breast cancer(LBC) has also been documented in some HDGC families. Here we report a 86 members family, with a deleterious CDH1 germline mutation identified in 3 LBC affected members on 2 successive generations, 2 of them being bilateral LBC cases. It is noteworthy that no DGC was observed in this family. Subjects and Methods The family is of Caucasian origin, with 5 women affected by breast cancers. The proband is a female diagnosed with ILBC at the age of 60, her daughter was diagnosed with bilateral ILBC at the age of 42, one of her sisters died of breast cancer diagnosed at the age of 53, histological type was unknown. Two of her cousins were also diagnosed with breast cancer at the age of 63 and 54 respectively (one is a bilateral ILBC, another unknown). There is no confirmed diffused gastric cancer diagnosis in the history of this family. The affected members, their offspring, and siblings were recruited for genetic consultation. Two independent blood samples were tested after signing informed consent for each family member. Complete screening of CDH1, BRCA1 and BRCA2 genes was performed on 7 cases by sequencing exons and intron-exon boundaries. Results No BRCA1 and BRCA2 mutations were found in the family. A CDH1 Q95X germ-line mutation was found in all the 3 living women with invasive lobular breast cancers (2 of them developed bilateral ILBCs) and a 71-year-old healthy male member (one of the brothers of the proband). The mutation is also present in an obligatory carrier woman who developed a pancreatic cancer at the age of 56. Gastrointestinal endoscopy was recommended for indicative living individuals during genetic consultations, when they harbored the CDH1 mutations. No suspected gastric lesion was found. Conclusion Our report demonstrates the first clear example of the involvement of a deleterious E-cadherine germ-line mutation in inherited invasive lobular breast carcinoma. Screening for CDH1 mutation should be considered in families with multiple ILBC cases, even in the absence of DGC cases; ILBC risk should be considered for female carriers during consultations; prophylactic gastrectomy may not be regularly recommended in CDH1 mutations carriers without family histories of DGC. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1842.
Title: Abstract 1842: Familial demonstration of the involvement of E-cadherine germ-line mutation in inherited invasive lobular breast carcinomas
Description:
Abstract Introduction Germline mutations of the CDH1 (epithelial cadherin, OMIM 192090) gene have been extensively studied in hereditary diffuse gastric cancer (HDGC) families.
Carriers of CDH1 germline mutations have a cumulative gastric cancer risk of 40-67% for men and 63-83% for women.
Putative associated risk of lobular breast cancer(LBC) has also been documented in some HDGC families.
Here we report a 86 members family, with a deleterious CDH1 germline mutation identified in 3 LBC affected members on 2 successive generations, 2 of them being bilateral LBC cases.
It is noteworthy that no DGC was observed in this family.
Subjects and Methods The family is of Caucasian origin, with 5 women affected by breast cancers.
The proband is a female diagnosed with ILBC at the age of 60, her daughter was diagnosed with bilateral ILBC at the age of 42, one of her sisters died of breast cancer diagnosed at the age of 53, histological type was unknown.
Two of her cousins were also diagnosed with breast cancer at the age of 63 and 54 respectively (one is a bilateral ILBC, another unknown).
There is no confirmed diffused gastric cancer diagnosis in the history of this family.
The affected members, their offspring, and siblings were recruited for genetic consultation.
Two independent blood samples were tested after signing informed consent for each family member.
Complete screening of CDH1, BRCA1 and BRCA2 genes was performed on 7 cases by sequencing exons and intron-exon boundaries.
Results No BRCA1 and BRCA2 mutations were found in the family.
A CDH1 Q95X germ-line mutation was found in all the 3 living women with invasive lobular breast cancers (2 of them developed bilateral ILBCs) and a 71-year-old healthy male member (one of the brothers of the proband).
The mutation is also present in an obligatory carrier woman who developed a pancreatic cancer at the age of 56.
Gastrointestinal endoscopy was recommended for indicative living individuals during genetic consultations, when they harbored the CDH1 mutations.
No suspected gastric lesion was found.
Conclusion Our report demonstrates the first clear example of the involvement of a deleterious E-cadherine germ-line mutation in inherited invasive lobular breast carcinoma.
Screening for CDH1 mutation should be considered in families with multiple ILBC cases, even in the absence of DGC cases; ILBC risk should be considered for female carriers during consultations; prophylactic gastrectomy may not be regularly recommended in CDH1 mutations carriers without family histories of DGC.
Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend.
Citation Format: {Authors}.
{Abstract title} [abstract].
In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC.
Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1842.

Related Results

Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract Introduction Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Desmoid-Type Fibromatosis of The Breast: A Case Series
Desmoid-Type Fibromatosis of The Breast: A Case Series
Abstract IntroductionDesmoid-type fibromatosis (DTF), also called aggressive fibromatosis, is a rare, benign, locally aggressive condition. Mammary DTF originates from fibroblasts ...
Analysis of SMOC2 gene variants in familial and non-familial primary open angle glaucoma Pakistani patients
Analysis of SMOC2 gene variants in familial and non-familial primary open angle glaucoma Pakistani patients
AIM: To find out the association of secreted protein acidic and rich in cysteine (SPARC)-related modular calcium binding 2 (SMOC2) gene variants rs2255680 and rs13208776 with genot...
Abstract 2271: bcl-2 expression in HER2-positive breast carcinoma subtypes
Abstract 2271: bcl-2 expression in HER2-positive breast carcinoma subtypes
Abstract Background: HER2-positive breast cancers comprise 20-30% of all breast cancers; amplification of HER2 confers a poorer prognosis. While treatment with anti-...
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract Women with one or more first-degree female relatives with a history of breast cancer have a two-fold increased risk of developing breast cancer. This risk i...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...

Back to Top